• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ten Top Tips for the Management of GLP-1 Receptor Agonists in Adults within Primary Care.

作者信息

Dobbie Laurence J, Parretti Helen M, Fallows Ellen, Le Brocq Sarah, De Giorgio Stephanie, McGowan Barbara, Patel Dipesh

机构信息

Obesity Management Collaborative UK (OMC-UK), London, UK.

School of Life Course & Population Sciences, Kings College London, London, UK.

出版信息

Obes Facts. 2025 May 19:1-6. doi: 10.1159/000546472.

DOI:10.1159/000546472
PMID:40388902
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12194299/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e9f/12194299/8f297f0f0930/ofa-2025-0000-0000-546472_F02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e9f/12194299/ebe855f1bb0e/ofa-2025-0000-0000-546472_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e9f/12194299/8f297f0f0930/ofa-2025-0000-0000-546472_F02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e9f/12194299/ebe855f1bb0e/ofa-2025-0000-0000-546472_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e9f/12194299/8f297f0f0930/ofa-2025-0000-0000-546472_F02.jpg

相似文献

1
Ten Top Tips for the Management of GLP-1 Receptor Agonists in Adults within Primary Care.基层医疗中成人GLP-1受体激动剂管理的十大顶级建议。
Obes Facts. 2025 May 19:1-6. doi: 10.1159/000546472.
2
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.七种胰高血糖素样肽-1 受体激动剂和多激动剂在肥胖或超重患者中的减肥作用：一项更新的随机对照试验的系统评价和网络荟萃分析。
Metabolism. 2024 Dec;161:156038. doi: 10.1016/j.metabol.2024.156038. Epub 2024 Sep 19.
3
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.钠-葡萄糖协同转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病成人患者：临床实践指南。
BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.
4
The Impact and Safety of GLP-1 Agents and Breast Cancer.胰高血糖素样肽-1（GLP-1）受体激动剂与乳腺癌的影响及安全性
Cancer Med. 2025 Jun;14(12):e70932. doi: 10.1002/cam4.70932.
5
Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis.GLP-1 受体激动剂与 SGLT-2 抑制剂在超重/肥胖伴或不伴糖尿病患者中的疗效和安全性：系统评价和网络荟萃分析。
BMJ Open. 2023 Mar 7;13(3):e061807. doi: 10.1136/bmjopen-2022-061807.
6
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.成人超重和肥胖的药物治疗：随机对照试验的系统评价和网络荟萃分析。
Lancet. 2024 Apr 6;403(10434):e21-e31. doi: 10.1016/S0140-6736(24)00351-9.
7
Transforming Care: Implications of Glucagon Like Peptide-1 Receptor Agonists on Physical Therapist Practice.变革护理：胰高血糖素样肽-1受体激动剂对物理治疗师实践的影响
Phys Ther. 2025 Jun 2;105(6). doi: 10.1093/ptj/pzaf061.
8
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂治疗 2 型糖尿病：随机对照试验的系统评价和网络荟萃分析。
BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573.
9
Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.药物治疗 2 型糖尿病的获益与危害：随机对照试验的系统评价和网络荟萃分析。
BMJ. 2023 Apr 6;381:e074068. doi: 10.1136/bmj-2022-074068.
10
Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis.THR-β 激动剂、FGF-21 类似物、GLP-1R 激动剂、GLP-1 为基础的多激动剂和全 PPAR 激动剂治疗 MASLD 的疗效比较：系统评价和网络荟萃分析。
Metabolism. 2024 Dec;161:156043. doi: 10.1016/j.metabol.2024.156043. Epub 2024 Sep 30.

本文引用的文献

1
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.司美格鲁肽处方治疗患者发生非动脉炎性前部缺血性视神经病变的风险。
JAMA Ophthalmol. 2024 Aug 1;142(8):732-739. doi: 10.1001/jamaophthalmol.2024.2296.
2
Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review.胰高血糖素样肽-1 受体激动剂与甲状腺癌：一篇叙述性综述。
Thyroid. 2024 Apr;34(4):403-418. doi: 10.1089/thy.2023.0530. Epub 2024 Mar 26.
3
The GLP-1 journey: from discovery science to therapeutic impact.胰高血糖素样肽-1的历程：从发现科学到治疗作用
J Clin Invest. 2024 Jan 16;134(2):e175634. doi: 10.1172/JCI175634.
4
Association of semaglutide with risk of suicidal ideation in a real-world cohort.在真实世界队列中，司美格鲁肽与自杀意念风险的关联。
Nat Med. 2024 Jan;30(1):168-176. doi: 10.1038/s41591-023-02672-2. Epub 2024 Jan 5.
5
ASA Consensus-based Guidance on Preoperative Management of Patients on Glucagon-like Peptide-1 Receptor Agonists.美国麻醉医师协会基于共识的胰高血糖素样肽-1受体激动剂治疗患者术前管理指南。
Anesthesiology. 2024 Feb 1;140(2):346-348. doi: 10.1097/ALN.0000000000004776.
6
Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review.GLP1RA 对多囊卵巢综合征妇女妊娠率和月经周期的影响：荟萃分析和系统评价。
BMC Endocr Disord. 2023 Nov 8;23(1):245. doi: 10.1186/s12902-023-01500-5.
7
Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence.GLP-1 激动剂和 SGLT2 抑制剂在妊娠和哺乳期对后代结局的影响：证据的系统评价。
Front Endocrinol (Lausanne). 2023 Oct 10;14:1215356. doi: 10.3389/fendo.2023.1215356. eCollection 2023.
8
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice.管理肥胖症中 GLP-1 受体激动剂的胃肠道副作用：临床实践建议。
Postgrad Med. 2022 Jan;134(1):14-19. doi: 10.1080/00325481.2021.2002616. Epub 2021 Nov 29.
9
Once-Weekly Semaglutide in Adults with Overweight or Obesity.每周一次司美格鲁肽在超重或肥胖成人中的应用。
N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10.
10
Double burden of malnutrition in persons with obesity.肥胖人群的营养不良双重负担。
Rev Endocr Metab Disord. 2020 Sep;21(3):307-313. doi: 10.1007/s11154-020-09578-1.